Publication | Closed Access

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

Minor Fold ChangesPrimary MutationsSecond-generation Resistance ProfilesMedicineImmunologyAntiviral Drug DevelopmentResistance Mutation (Virology)VirologyAntiviral TherapyAntiviral DrugSystems BiologyPharmacologyAntimicrobial ResistanceDrug DiscoveryDrug Resistance